Finland In-Vitro Diagnostic Market

Finland In-Vitro Diagnostics Market Overview

The Finland In-Vitro Diagnostics Market size was valued at USD 440.38 million in 2023, and is predicted to reach USD 686.92 million by 2030, at a CAGR of 6.1% from 2024 to 2030. In-Vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Growing chronic disease incidence in Finland Drives In-Vitro Diagnostics Market Growth

The increasing incidence of chronic diseases is boosting the need for advanced diagnostic techniques, thereby propelling the growth of the in-vitro diagnostics market. According to European Observatory on Health System and Policies, in 2021, the primary causes of mortality in Finland were circulatory diseases, specifically ischemic heart diseases and stroke, followed by cancer, Alzheimer’s and other dementias. Collectively, these ailments constituted approximately three-quarters of all reported deaths in Finland. 

Medical Equipment Dominance in Finland Drives In-Vitro Diagnostics Market Growth

The prominence of medical equipment as the largest health technology segment in Finland, coupled with its substantial export value, is poised to drive growth in the in-vitro diagnostics market in the country. According to International Trade Administration, in 2022, Finland exported medical equipment worth USD 1.7 billion, making it the largest segment in the country's health technology sector. This accounts for 63 percent of Finland's total health technology exports. Finland's substantial export of medical equipment, which includes devices and instruments used in medical diagnosis and treatment, provides a solid foundation for advancing diagnostic technologies such as In-Vitro diagnostics.

High Research, Development, and Regulatory Approval Costs Hinder Vitro Diagnostics Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. 

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of growth in the in-vitro diagnostics (IVD) market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the Finland in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Finland In-Vitro Diagnostic Market Key Segments

By Type

• Reagents

• Instruments

• Software & Services

By Technique

• Immunodiagnostics

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Rapid Tests

  • Chemiluminescence Immunoassay (CLIA)

  • Enzyme-linked Immunosorbent spot (ELISpot)

  • Radioimmunoassay (RIA)

  • Western Blot

• Hematology

• Molecular Diagnostics

  • PCR

    • Monoplex PCR

    • Multiplex PCR

  • INAAT 

  • Hybridization 

  • DNA diagnostics 

  • Microarray 

  • Other Molecular Diagnostics

• Tissue Diagnostics

• Clinical Chemistry

  • Basic Metabolic Panel 

  • Liver Panel

  • Renal Profile

  • Lipid Profile

  • Thyroid Function Panel 

  • Electrolyte Panel 

  • Speciality Chemicals

• Other IVD Techniques

By Application

• Infectious Diseases

• Cancer

• Cardiac Diseases

• Immune System Disorders

• Nephrological Diseases

• Gastrointestinal Diseases

• Others

By End User

• Stand Alone Laboratory

• Hospitals

• Academics and Medical Schools

• Point of Care Testing

• Other End Users

Key Players

• Roche Holding AG

• Abbott Laboratories

• Thermo Fisher Scientific Inc

• Danaher Corporation

• Becton, Dickinson and Company

• Siemens Healthineers AG

• bioMérieux SA

• Sysmex Corporation

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

REPORT SCOPE AND SEGMENTATION: